Investment Thesis
Skye Bioscience is in severe financial distress with no meaningful revenue, $43.1M annual operating cash burn, and only $5.9M in cash reserves—creating an estimated runway of 1-2 months before liquidity crisis. Deeply negative profitability metrics (ROE -279%, ROA -197%) combined with deteriorating EPS (-93% YoY) indicate the company is not on a viable path to commercialization or profitability.
Strengths
- Minimal debt burden ($45.6K long-term debt) reduces refinancing risk
- Positive stockholders' equity of $20M provides some balance sheet cushion
- Low financial leverage preserves bankruptcy distance
Risks
- Critical cash runway: $5.9M cash against $43.1M annual burn equals 1-2 months to depletion
- Zero revenue generation suggests failed commercialization or pre-revenue stage in capital-intensive pharma sector
- Severely deteriorating fundamentals with EPS down 93% YoY and persistent operating losses of $58M+
Key Metrics to Watch
- Cash balance and monthly burn rate trajectory
- Announcements of financing, partnerships, or revenue-generating catalysts
- Operating expense reduction initiatives and path to profitability
Financial Metrics
Revenue
N/A
Net Income
-55.9M
EPS (Diluted)
$-1.41
Free Cash Flow
-43.1M
Total Assets
28.3M
Cash
5.9M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-279.3%
ROA
-197.5%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
3.30x
Quick Ratio
3.30x
Debt/Equity
0.00x
Debt/Assets
29.3%
Interest Coverage
N/A
Long-term Debt
45.6K
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-16T00:03:23.428326 |
Data as of: 2025-12-31 |
Powered by Claude AI